Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo [Phase 2]

View source ↗

Summary

A Phase II trial evaluating two doses of LTX-109 for impetigo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo

Drugs mentioned

• LTX-109

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Non-bullous Impetigo | Phase 2 | Status: COMPLETED